The Emergence of Multi-modal Real-world data: The power of Clinico-Genomic data versus traditional RWD Sources is a new #whitepaper that explores crucial and emerging topics, such as: • Why biomarker and genomic data matters for life science • How these data sources unlock what’s been missing from traditional RWD sources • How these newly created longitudinal data sets support drug development from discovery to trial to post-market • Why longitudinal data matters for developing targeted treatments for rare or complex conditions such as multiple myeloma • How tokenization allows for better integration of disparate data sources and meets the scrutiny of peer review and regulatory approval Visit us online to read this whitepaper: https://lnkd.in/gRYNims7 #NeoGenomics #RWD #Oncology
NeoGenomics Laboratories’ Post
More Relevant Posts
-
I help biotech and medical diagnostic organizations and teams connect the dots, execute their vision and deliver strong ROI.
Few diseases are as complex as hematological cancers. The number of alternative treatments considered for patients at different points throughout their care is more varied and individualized than what is seen in diagnosis and management of solid tumors. Hematological malignancies require surveillance of patients over multiple time periods with numerous clinical and diagnostic measures to assess sustained response to treatment or relapse. Learn more about how NeoGenomics worked with ConcertAI to establish a robust and definitive (RWE) hematology solution.
The Emergence of Multi-modal Real-world data: The power of Clinico-Genomic data versus traditional RWD Sources is a new #whitepaper that explores crucial and emerging topics, such as: • Why biomarker and genomic data matters for life science • How these data sources unlock what’s been missing from traditional RWD sources • How these newly created longitudinal data sets support drug development from discovery to trial to post-market • Why longitudinal data matters for developing targeted treatments for rare or complex conditions such as multiple myeloma • How tokenization allows for better integration of disparate data sources and meets the scrutiny of peer review and regulatory approval Visit us online to read this whitepaper: https://lnkd.in/gRYNims7 #NeoGenomics #RWD #Oncology
To view or add a comment, sign in
-
The DeciBio reports team has been busy, adding our Oncology Liquid Biopsy report to the list of reports published this year! Up next is the second edition of our Digital & Computational Pathology report, which is expected to be published in Q3 and will feature a new section on the use of image analysis and AI tools. Check out our website to purchase or find more information about any of these reports: https://lnkd.in/gpYWAsiT Fill out this form to add yourself to the notification list for any of our upcoming reports: https://lnkd.in/g4gTx6xN Reach out to Andrew Aijian or Rebecca Burnham, PhD if you're interested in subscribing to our entire report / content library. We’d also love to hear of any ideas for report topics that you’d like to see us publish on in the future - let us know in the comments! #precisionmedicine #spatialbiology #liquidbiopsy #biomarkers #diagnostics #digitalpathology #singlecell #genomics #proteomics #cellomics #oncology #celltherapy #research #pharma #drugdiscovery #clinicalresearch #marketresearch
To view or add a comment, sign in
-
Molecular diagnostics are rapidly transforming disease diagnosis and treatment! Our in-depth report, Molecular Diagnostics in Oncology, Genetic Diseases, and NIPT: 2023-2028, offers a comprehensive exploration of the technologies and dynamic market forces shaping the future of healthcare in these critical areas. Discover what's inside! Access the table of contents today and see what topics our report covers. Download here: https://hubs.la/Q02d655M0 Companies profiled include: Abbott | Diagnostics , Dako, Becton, Dickinson and Company, BGI Genomics, Exact Sciences, Guardant Health, Hologic, Inc., Illumina, and so many more! #moleculardiagnostics #oncology #geneticdiseases
To view or add a comment, sign in
-
Mark your calendars for September 10th! Velsera's webinar will explore the complexities of oncology variant analysis and present CGW Plus, our reimagined solution for clinical genomics. Learn how to automate and accelerate the analysis of genomic alterations. Register now! https://lnkd.in/g5guzA8C #EraofVelsera #Genomics #Webinar #ClinicalGenomics #PrecisionMedicine
To view or add a comment, sign in
-
The success of your research depends on the methodic and accurate selection of the most relevant tumor models. Lumin, Champions' integrated software solution, eliminates the guesswork and gives you access to the most comprehensive model characterization data in the industry. Explore Champions’ patient-derived preclinical model characteristics: ☑️Clinical annotations ☑️Proprietary genomic and proteomic profiles ☑️Proprietary in vivo pharmacological profiles Make data-driven decisions with confidence and accelerate your oncology research programs. Explore here: https://hubs.li/Q02y21pL0 #Lumin #modelselection #omics #genomics #proteomics #oncologyresearch #cancerresearch #clinicalannotations #oncology
To view or add a comment, sign in
-
Check our latest article ''Why a multi-faceted oncology toolkit is essential for precision medicine'' in collaboration with Jérôme Sallette, our Chief Scientific Officer. In the article we dive deep into the key elements of a successful precision medicine strategy, including the interplay of innovative, customizable testing capabilities, from flow cytometry to genomics and spatial omics. A must-read if you want to achieve more predictive biomarker assessment and shorten the timeline to better oncology trials and therapies. Read more here: https://lnkd.in/eqz__kgj #TransformingResearch #AdvancingHealth #ClinicalResearch #PrecisionMedicine
To view or add a comment, sign in
-
Mark your calendars for September 10th! Velsera's webinar will explore the complexities of oncology variant analysis and present CGW Plus, our reimagined solution for clinical genomics. Learn how to automate and accelerate the analysis of genomic alterations. Register now! https://lnkd.in/e7YrMfJg #EraofVelsera #Genomics #Webinar #ClinicalGenomics #PrecisionMedicine
Tackling Complexity in Oncology Variant Analysis with CGW Plus
velsera.com
To view or add a comment, sign in
-
Next-generation sequencing (NGS) has been transforming clinical practice for some time now, becoming a standard approach for diagnosing rare diseases, inherited cancers, and other genetic conditions. Clinicians are increasingly using NGS to guide personalized cancer treatments, helping to overcome the challenge of multi-drug resistant tumors. However, despite its growing adoption, there are still gaps in fully utilizing NGS in clinical settings. One significant challenge is the complexity of analyzing NGS data, particularly variant annotation and interpretation, which require a deep understanding of specialized tools and methods. As tools and methods for NGS data analysis continue to evolve, staying up-to-date with the latest advancements is essential for anyone working in clinical genomics. To support clinicians and researchers, we've designed our upcoming workshop to reflect the latest developments in clinical NGS. This workshop will comprehensively cover the concepts and techniques required for effective NGS data analysis in the clinic. Whether you're a beginner or looking to deepen your expertise, this workshop is the ideal opportunity to reskill and prepare yourself for the future of healthcare. Register today and secure your spot: https://lnkd.in/dkVH735N 📅 Workshop starts in just 5 days—don’t miss out! #NGS #Bioinformatics #PrecisionMedicine #Oncogenomics #ClinicalGenomics
To view or add a comment, sign in
-
Want to gain expert insights into protein spatial phenotyping and spatial signature development? Download our guide, which covers: ✔️ Harnessing Spatial Biology to Bridge the Immuno-Oncology Biomarker Gap ✔️ Spatial Biomarkers and Multiplex Imaging in Immuno-Oncology ✔️ Developing a Reproducible Multiplex Imaging Workflow ✔️ Certainty in Imaging – Generating Quantitative Information ✔️ Multiplex Imaging Analysis #spatialbiology #immunooncology #biomarkers #spatialphenotyping
eBOOK: Spatial Phenotyping in Clinical and Translational Research
https://www.akoyabio.com
To view or add a comment, sign in
-
For anyone in my network traveling to Barcelona next week for #ESMO24, stop by Booth #422 if you're looking to have a deep dive into how real-world data (DNA-seq + RNA-seq + whole slide images + linked longitudinal treatment and outcomes data) can power your clinical pipelines. 🌐 With access to 200k+ tumor biopsies, Tempus is transforming cancer research with multimodal data, including genomic, transcriptomic, and imaging insights. From novel target discovery to biomarker development and companion diagnostics, we are driving critical decisions that accelerate drug development. Our capabilities span across: 🔹 Real-world DNA, RNA, imaging, longitudinal clinical data 🔹 Validating biomarkers with tumor-derived organoids 🔹 Supporting clinical trial design with real-world data 🔹 Companion diagnostic development using broad-panel NGS assays 🔹 Evidence generation for label expansion Come by to discuss how Tempus data can supercharge your research. Or just stop by for a chat! See you in Barcelona! 🇪🇸 #Oncology #ClinicalTrials #RealWorldData #PrecisionMedicine #DrugDevelopment #ESMO2024 #Biotech #Tempus
To view or add a comment, sign in
33,297 followers